Miguel, J., Araujo, L. H., & Costa, R. (2020). Cost-effectiveness of erlotinib compared to gefitinib for NSCLC with EGFR mutations at the Inca. Jornal Brasileiro De Economia Da Saúde, 12(1), 8–15. https://doi.org/10.21115/JBES.v12.n1.p8-15